Effect and prognosis of extracorporeal membrane oxygenation in the treatment of respiratory failure

doi:10.3760/cma.j.issn.1007-1245.2023.07.019

Abstract

Abstract:

Objective　To investigate the effect and prognosis of extracorporeal membrane oxygenation (ECMO) in the treatment of respiratory failure. Methods　This study was a retrospective study. A total of 84 respiratory failure patients diagnosed and treated in Huangshi Central Hospital from May 2019 to June 2022 were selected as the research objects. According to treatment methods, they were divided into an observation group (receiving ECMO treatment) and a control group (receiving invasive positive pressure mechanical ventilation treatment), with 42 cases in each group. In the observation group, there were 21 males and 21 females, aged (55.82±2.41) years; in the control group, there were 22 males and 20 females, aged (55.62±2.36) years. The airway resistance (RAW), airway peak pressure (P_peak), static compliance (Cst), surplus pulse O₂ (SpO₂), partial pressure of arterial carbon dioxide (PaCO₂), partial pressure of arterial oxygen (PaO₂), forced expiratory volume in 1 second (FEV₁), percentage of forced expiratory volume in 1 second to forced vital capacity (FEV₁/FVC), peak expiratory flow (PEF), endothelin (ET-1), Clara cell secretion protein 16 (CC16), Copeptin, 28 d mortality, withdrawal success rate, and ventilation time were compared between the two groups. Independent sample t test and χ² test were performed. Results　Before treatment, there were no statistically significant differences in the RAW, Cst, P_peak, SpO₂, PaCO₂, PaO₂, FEV₁, FEV₁/FVC, ET-1, CC16, and Copeptin between the two groups (all P>0.05). After treatment, the RAW, Cst, PaCO₂, ET-1, CC16, and Copeptin of the observation group were (16.42±1.78) cmH₂O/L•s (1 cmH₂O=0.098 kPa), (27.41±5.62) cmH₂O, (50.01±6.32) mmHg (1 mmHg= 0.133 kPa), (14.21±2.32) ng/L, (0.18±0.03) ng/L, and (28.62±6.85) ng/L, which were significantly lower than those of the control group [(18.05±2.36) cmH₂O/L•s, (25.05±4.11) cmH₂O, (53.85±8.47) mmHg, (26.65±3.96) ng/L, (0.29±0.08) ng/L, and (35.74±9.52) ng/L] (all P<0.05). The P_peak, SpO₂, PaO₂, FEV₁, FEV₁/FVC, and PEF of the observation group were (14.65±1.44) cmH₂O, (96.45±17.05) %, (70.52±8.96) mmHg, (61.25±8.45) %, (68.74±9.45) %, and (4.89±0.56) L/s, which were significantly higher than those of the control group [(16.05±1.96) cmH₂O, (94.11±15.14) %, (68.01±6.85) %, (48.33±6.45) %, (59.78±6.08) %, and (4.24±0.39) L/s] (all P<0.05). The 28 d mortality rate of the observation group was 9.52% (4/42), which was lower than that of the control group [28.57% (12/42)]; the ventilation time of the observation group was (9.52±2.32) d, which was shorter than that of the control group [(11.36±3.69) d]; the withdrawal success rate of the observation group was 95.24% (40/42), which was higher than that of the control group [73.81% (31/42)] (all P<0.05). Conclusion　ECMO has an ideal effect in the treatment of respiratory failure, which is beneficial to improve the blood gas analysis indexes and reduce the mortality rate.

Key words:

Extracorporeal membrane oxygenation, , Respiratory failure, , Pulmonary function, , Blood gas analysis, , Prognosis

摘要：

目的　探讨体外膜肺氧合（ECMO）治疗呼吸衰竭的效果及预后。方法　本研究为回顾性研究。选取2019年5月至2022年6月黄石市中心医院诊治的84例呼吸衰竭患者作为研究对象，按照治疗方法分为观察组（予以ECMO治疗）与对照组（予以有创正压机械通气治疗）各42例。观察组中，男性21例、女性21例，年龄（55.82±2.41）岁；对照组中，男性22例、女性20例，年龄（55.62±2.36）岁。对比两组气道阻力（RAW）、气道峰压（P_peak）、静态顺应性（Cst）、脉搏血氧饱和度（SpO₂）、动脉血二氧化碳分压（PaCO₂）、动脉血氧分压（PaO₂）、第1秒用力呼气容积（FEV₁）、第1秒用力呼气容积占用力肺活量的百分比（FEV₁/FVC）、最大呼气流量（PEF）、内皮素-1（ET-1）、Clara细胞分泌蛋白16（CC16）、和肽素（Copeptin）、28 d病死率、撤机成功率、通气时间。采用独立样本t检验、χ²检验。结果　治疗前，两组RAW、Cst、P_peak、SpO₂、PaCO₂、PaO₂、FEV₁、FEV₁/FVC、ET-1、CC16、Copeptin比较，差异均无统计学意义（均P>0.05）。治疗后，观察组的RAW、Cst、PaCO₂、ET-1、CC16、Copeptin分别为（16.42±1.78）cmH₂O/L•s（1 cmH₂O=0.098 kPa）、（27.41±5.62）cmH₂O、（50.01±6.32）mmHg（1 mmHg=0.133 kPa）、（14.21±2.32）ng/L、（0.18±0.03）ng/L、（28.62±6.85）ng/L，显著低于对照组的（18.05±2.36）cmH₂O/L•s、（25.05±4.11）cmH₂O、（53.85±8.47）mmHg、（26.65±3.96）ng/L、（0.29±0.08）ng/L、（35.74±9.52）ng/L（均P<0.05）；观察组P_peak、SpO₂、PaO₂、FEV₁、FEV₁/FVC、PEF分别为（14.65±1.44）cmH₂O、（96.45±17.05）%、（70.52±8.96）mmHg、（61.25±8.45）%、（68.74±9.45）%、（4.89±0.56）L/s，显著高于对照组的（16.05±1.96）cmH₂O、（94.11±15.14）%、（68.01±6.85）%、（48.33±6.45）%、（59.78±6.08）%、（4.24±0.39）L/s（均P<0.05）。观察组的28 d病死率9.52%（4/42）低于对照组28.57%（12/42），通气时间（9.52±2.32）d短于对照组（11.36±3.69）d，撤机成功率95.24%（40/42）高于对照组73.81%（31/42）（均P<0.05）。结论　ECMO治疗呼吸衰竭具有较为理想效果，有利于改善血气分析指标和降低病死率。

关键词:

体外膜肺氧合, 呼吸衰竭, 肺功能, 血气分析, 预后

Yuan Fawei, Li Bingqi.

Effect and prognosis of extracorporeal membrane oxygenation in the treatment of respiratory failure [J]. International Medicine and Health Guidance News, 2023, 29(7): 973-977.

袁法伟李炳奇.

体外膜肺氧合治疗呼吸衰竭的效果及预后分析 [J]. 国际医药卫生导报, 2023, 29(7): 973-977.

References

[1] 马彩霞,王玉,张露露,等.体外膜肺氧合治疗重症呼吸衰竭患儿12例临床分析[J].中华实用诊断与治疗杂志,2020,34(7):718-721. DOI:10.13507/j.issn.1674-3474.2020. 07.019.
[2] 尹德成,赵喆,刘颖悦,等.重症患儿院间体外膜肺氧合转运的临床回顾性分析[J].第三军医大学学报,2019,41(1):19-24. DOI:10.16016/j.1000-5404.201806043.
[3] 王一雪,杨雪,陈伟明,等.长时间静脉-动脉体外膜肺氧合合并碳青霉烯类耐药肺炎克雷伯菌血流感染一例并文献复习[J].中国小儿急救医学,2021,28(7):633-636. DOI:10.3760/cma.j.issn.1673-4912.2021.07.019.
[4] 甘艳如,春晓,马敬香,等.体外膜肺氧合治疗重症腺病毒肺炎合并急性呼吸窘迫综合征患儿的护理体会[J].中国实用护理杂志,2020,36(11):833-837. DOI:10.3760/cma.j.cn211501-20191003-02784.
[5] 彭晓鹏,周成斌,黄劲松,等.体外膜肺氧合技术在人工心脏瓣膜置换术后泵衰竭中的应用[J].岭南心血管病杂志,2020,26(2):176-179,194. DOI:10.3969/j.issn.1007-9688. 2020.02.10.
[6] 郑丽,牟春英,黎巧玲.1例重症肺炎患者体外膜肺氧合联合连续性肾脏替代及机械通气治疗的康复护理[J].现代临床护理,2021,20(9):81-85. DOI:10.3969/j.issn.1671-8283. 2021.9.015.
[7] 朱永亮,许进明,华岚,等.体外膜肺氧合治疗呼吸循环衰竭患者的输血特征及影响因素分析[J].中国输血杂志,2020,33(10):1055-1058. DOI:10.13303/j.cjbt.issn.1004- 549x.2020.10.014.
[8] 张华忠,陈旭锋,梅勇,等.54例成人体外膜肺氧合辅助心肺复苏的有效性和年成本-效果分析[J].中华急诊医学杂志,2021,30(10):1197-1201. DOI:10.3760/cma.j.issn.1671- 0282.2021.10.007.
[9] Mustafa AK, Joshi DJ, Alexander PJ, et al. Comparative propensity matched outcomes in severe COVID-19 respiratory failure-extracorporeal membrane oxygenation or maximum ventilation alone[J]. Ann Surg, 2021, 274(5):e388-e394. DOI: 10.1097/SLA.0000000000005187.
[10] 柳红娟,乔莹,陈晗睿,等.2例暴发性心肌炎清醒患者使用体外膜肺氧合联合主动脉内球囊反搏治疗的护理[J].中华护理杂志,2021,56(12):1796-1799. DOI:10.3761/j.issn.0254-1769.2021.12.006.
[11] Li C, Xie H, Li J, et al. Dynamic and hybrid configurations for extracorporeal membrane oxygenation: an analysis of the Chinese extracorporeal life support registry[J]. ASAIO J, 2022, 68(4):547-552. DOI: 10.1097/MAT.0000000000001535.
[12] 张韫佼,梅举,许喜乐,等.心胸外科术后使用体外膜肺氧合治疗重度心肺功能不全23例临床分析[J].中国心血管病研究,2021,19(3):236-241. DOI:10.3969/j.issn.1672-5301. 2021.03.009.
[13] Nagler B, Hermann A, Robak O, et al. Incidence and etiology of system exchanges in patients receiving extracorporeal membrane oxygenation[J]. ASAIO J, 2021, 67(7):776-784. DOI: 10.1097/MAT.0000000000001332.
[14] 王海玉,刘金蓉,梅珊珊,等.不同孕周及方法测量的观察-预期肺头比对先天性左侧膈疝胎儿生后符合体外膜肺氧合指征的预测价值[J].中华围产医学杂志,2022,25(1):53-58. DOI:10.3760/cma.j.cn113903-20210704-00604.
[15] Rabie AA, Asiri A, Rajab M, et al. Beyond frontiers: feasibility and outcomes of prolonged veno-venous extracorporeal membrane oxygenation in severe acute respiratory distress syndrome[J]. ASAIO J, 2021, 67(3):339-344. DOI: 10.1097/MAT.0000000000001367.
[16] 李剑,傅佳鹏,刘志超,等.早期有创呼吸机辅助通气治疗胸膜肺切除术的结核性毁损肺患者78例临床观察[J].山东医药,2021,61(34):73-76. DOI:10.3969/j.issn.1002- 266X.2021.34.018.
[17] 谭营帅,曹凤安,李军,等.静脉-静脉体外膜肺氧合治疗重度急性呼吸窘迫综合征的影响因素[J].中国急救医学,2021,41(12):1023-1027. DOI:10.3969/j.issn.1002-1949.2021. 12.003.
[18] Mark A, Crumley JP, Rudolph KL, et al. Maintaining mobility in a patient who is pregnant and has COVID-19 requiring extracorporeal membrane oxygenation: a case report[J]. Phys Ther, 2021, 101(1):pzaa189. DOI: 10.1093/ptj/pzaa189.